The linked FDA record for Medivis, Inc. centers on one 510(k) clearance. NeuroAlign, product code HAW, was assigned regulation number 21 CFR 882.4560 (Stereotaxic Instrument), Class II, in the Neurology advisory committee, with a decision of substantially equivalent dated October 26, 2026. The same applicant name appears on an earlier NeuroAlign software clearance, K231897, decided October 21, 2025. The company's own site describes a workflow spanning imaging, planning and navigation, and states that one referenced device is not cleared by the FDA and is not available for sale. [1][2][4][5]
The K261997 clearance and its stated basis
K261997 lists Medivis, Inc. as applicant, with device name NeuroAlign, product code HAW, regulation 21 CFR 882.4560, Class II, advisory committee Neurology, decision code SESE and decision date October 26, 2026. The record shows a Traditional clearance type, no third-party review, and a Summary as the statement or summary. The FDA letter for the same number is addressed to Amy Lynn, Chief Compliance Officer, at a New York, New York address, and repeats the trade name, regulation and product code. [1][2]
The letter describes shared characteristics with a predicate device: the same intended users, anatomical site, fundamental scientific technology and core operating principles. It lists pre-operative DICOM imaging datasets, optical infrared tracking, fiducial-based instrument localization, real-time stereotactic navigation software, three-dimensional anatomical visualization, and workstation-based image processing and display. These are descriptions of the technology, not statements of clinical performance. [2]
An earlier NeuroAlign software filing
A separate FDA letter covers K231897, trade name NeuroAlign software, under the same regulation 21 CFR 882.4560, Class II, product code HAW, addressed to the same Chief Compliance Officer at a different New York street address. That letter is dated October 21, 2025, with the submission dated December 20, 2024 and received December 23, 2024. The two filings share a device family name but are distinct submissions with distinct numbers and dates. [4]
The K231897 letter includes a statement about accuracy values and keeping system error within 2mm and 2 degrees, and reports that predetermined acceptance criteria were met. That language belongs to the earlier filing's review record; it is not presented here as a claim about K261997 or about clinical outcomes. [4]
What the company says about itself
Medivis states on its About page that it was founded in 2016 by physicians and engineers in New York City, and describes making augmented reality and artificial intelligence the standard of surgical care, with a plan built on the patient's own imaging and carried into the operating room in the surgeon's view. The page references an office in the Flatiron District of New York City and a milestones section describing progression to cleared navigation in the operating room. [7]
The homepage describes Medivis Studio turning imaging into a plan, Medivis Navigation carrying that plan to the patient as real-time guidance, and Frontier as closing the loop with systems that learn from every case. It also references spine navigation and AR Loupes. A disclaimer on the site states that a referenced device is not cleared by the FDA and is not available for sale, and that information about it rests on preliminary data. Which specific product that disclaimer covers is not identified in the public information. [5]
Scope and limits of the record
The supplied collection contains one linked 510(k) record, K261997, with a decision count of one substantially equivalent, and the record sample contains that same single entry. These are counts of the supplied filings as of the snapshot date, not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]
The FDA filing addresses are correspondence addresses in New York, New York, and are not treated here as a verified headquarters. No parent company, ownership structure, customer list, certification or commercial availability is established by the public documents. The company's founding year and location come from its own published About page, attributed to that publisher. [2][4][7]

